The Onder Law Firm Updates Actos Bladder Cancer Lawsuit Website

Attorneys handling Actos bladder cancer claims provide answers to most frequently asked questions regarding Actos bladder cancer lawsuits.

Sunday, September 30, 2012 - Actos, a drug used to control blood sugar in adults with Type 2 diabetes, was linked to an increase in bladder cancer risk, prompting the FDA to issue an Actos bladder cancer warning last updated on August 4, 2011 (fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm226257.htm). The Onder Law Firm, known for its handling of dangerous drug and defective medical device cases nationwide, created an Actos bladder cancer lawsuit website, providing information on Actos bladder cancer claims. After nearly a year of speaking with persons and the families of those, who have been diagnosed with bladder cancer after using Actos, the firm‘s Actos bladder cancer attorneys have updated the website with answers to the most frequently asked Actos bladder cancer claim questions.

Actos, marketed by Takeda Pharmaceuticals, Inc., the largest pharmaceutical firm in Japan, was approved by the FDA in 1999 and become the top-selling medication of its type in the United States, with more than 2 million users per year. The FDA issued the first of two Actos safety warning in 2007.

The Actos bladder cancer lawyers at The Onder Law Firm are offering a no-cost, no-obligation Actos bladder cancer lawsuit case review to those wishing to explore their legal rights. Actos bladder cancer lawsuits are not class action lawsuits; each Actos cancer case will be handled and settled individually based upon its own merits and the damage caused. The Onder Law Firm is handling all Actos bladder cancer cases on a contingency basis, meaning there are never any legal fees unless the firm‘s Actos bladder cancer lawyers are able to win a settlement.

The Onder Law Firm welcomes Actos bladder cancer inquiries from law firms wishing to refer their cases or working as co-counsel.

Other Actos Lawsuit Attorney News Releases:

Ad